The Egyptian International Pharmaceutical Industries Company’s (EIPICO) (PHAR) consolidated profits attributable to the parent company reached EGP 587.040 million in 2022, up from EGP 449.397 million in 2021, according to financial statements filed to the Egyptian Exchange (EGX) on March 1st.

Net sales surged to EGP 3.955 billion in the full year that ended December 31st 2022, from EGP 3.408 billion in 2021.

Standalone net profits after tax amounted to EGP 589.150 million last year, up from 483.917 million in 2021.

EIPICO is an Egypt-based public shareholding company that operates in the pharmaceutical industry. It is a manufacturer and exporter of pharmaceuticals and holds license agreements with a group of international.

 

Copyright © 2022 Arab Finance Brokerage Company All rights reserved. Provided by SyndiGate Media Inc. (Syndigate.info).